Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study

NCT03334318 is registered in ClinicalTrials.gov with Joslin Diabetes Center as lead sponsor.

NCT NCT03334318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03334318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
Lead sponsor
Joslin Diabetes Center
Phase
Observational
Overall status
Completed
Start date
October 1, 2017
Completion date
December 31, 2021
Enrollment
175 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathies